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Insulin-like growth factor-I (IGF-I) plays an important
role in regulating vascular smooth muscle cell (VSMC)
proliferation, migration, and apoptosis. The bioactivity
of IGF-I is modulated by a group of high affinity, specific
binding proteins (IGF-binding proteins; IGFBPs) that
are present in the interstitial fluid. Previously, we have
reported that porcine VSMCs synthesize and secrete
IGF-I and several forms of IGFBPs, including IGFBP-2,
IGFBP-4, and IGFBP-5. In this study, we examined the
role of autocrine/paracrine secreted IGF-I in controlling
the expression of IGFBP-4 and IGFBP-5 as well as the
effects of these IGFBPs in modulating the cellular rep-
lication response to IGF-I. The concentrations of IG-
FBP-4 in the conditioned medium increased signifi-
cantly from <50 ng/ml to 742 6 105 ng/ml. This increase
was associated with a decrease in the activity of an
IGF-I-regulated IGFBP-4 protease. In contrast, the syn-
thesis of IGFBP-5 was inversely correlated with culture
density, and its concentration decreased from 792 6 91
to 44 6 14 ng/ml. IGFBP-5 mRNA in sparse cultures was
3-fold higher compared with those in confluent cultures.
This culture density-dependent change in IGFBP-5
mRNA correlated closely with endogenous IGF-I levels.
Since treatment of VSMC with exogenous IGF-I in-
creased IGFBP-5 mRNA levels, we neutralized the effect
of endogenously secreted IGF-I with an anti-IGF-I anti-
body to determine if it would alter IGFBP-5 mRNA abun-
dance. This resulted in a 4.4-fold decrease in IGFBP-5
mRNA levels. When added together with IGF-I, exoge-
nous IGFBP-4 inhibited IGF-I-induced DNA synthesis in
a concentration-dependent manner. IGFBP-5, on the
other hand, potentiated the effect of IGF-I. Therefore,
IGFBP-4 and IGFBP-5 appear to be differentially regu-
lated by autocrine/paracrine IGF-I through distinct
mechanisms. These two proteins, in turn, play opposing
roles in modulating IGF-I action in stimulating VSMC
proliferation.
Vascular smooth muscle cell (VSMC)1 proliferation, apopto-
sis, and directed migration from arterial media into the intima
are critical events for the development of fibromuscular lesions
commonly associated with atherosclerosis. Several lines of ev-
idence suggest that insulin-like growth factor-I (IGF-I) plays
an important role in these processes. IGF-I mRNA and peptide
are detected in intimal lesions that develop after angioplasty,
and both their levels increase significantly after balloon denu-
dation injury (1–3). These increases temporally precede an
increase in VSMC proliferation. In vitro, IGF-I acts synergis-
tically with other growth factors to stimulate DNA synthesis
(4). Cultured VSMCs have been shown to express IGF-I mRNA
and secrete IGF-I (5–7). Specific inhibition of the endogenously
produced IGF-I, using a neutralizing antibody, resulted in de-
creased cell proliferation, which indicates that IGF-I acts as an
autocrine growth regulator in VSMCs (4). The IGF-I receptor,
which mediates the biological actions of the IGFs, is expressed
in VSMCs. Selective inhibition of the receptors by antisense
targeting results in marked reduction of VSMC proliferation
(8). Recent studies have demonstrated that IGF-I is a very
potent regulator of VSMC migration, and this action is medi-
ated by the IGF-I receptor (9, 10). It has been reported that
IGF-I also plays a crucial role in regulating VSMC apoptosis
(11, 12). These findings provide strong evidence to support the
concept that IGF-I is an autocrine/paracrine factor that regu-
lates VSMC proliferation, apoptosis, and migration.
The pericellular bioactivity of IGF-I in a defined tissue is not
only dependent on IGF-I and its receptors but is also influenced
by a group of high affinity specific binding proteins (IGFBPs)
that are present in the local environment. We have previously
shown that porcine VSMCs secrete three IGFBPs: IGFBP-2,
IGFBP-4, and IGFBP-5, with IGFBP-2 being the predominant
form (13, 14). Similarly, IGFBP-2, IGFBP-4, and IGFBP-5 have
been reported to be synthesized in rat and human VSMCs
(14–17). A recent study indicated that IGFBP-6 is secreted in
human VSMCs (18). Although these IGFBPs are believed to
play a role in modulating the biological actions of IGF-I in
VSMCs, their specific role and their interactions with the au-
tocrine/paracrine secreted IGF-I remain to be defined. To fur-
ther elucidate the roles of specific forms of IGFBPs that are
synthesized by VSMCs, we studied the expression and biolog-
ical effects of IGFBP-4 and IGFBP-5 in porcine VSMCs. The
results of the present study indicate that the extracellular fluid
concentrations of these two molecules are differentially regu-
lated by the autocrine/paracrine IGF-I through distinct mech-
anisms. Furthermore, IGFBP-4 and IGFBP-5 exhibited oppos-
ing effects in modulating the IGF-I-actions in this cell type.
EXPERIMENTAL PROCEDURES
Materials—Fetal bovine serum, Dulbecco’s minimum essential me-
dium (DMEM) with high glucose, and penicillin-streptomycin were
purchased from Life Technologies, Inc. Trypsin was obtained from
Boehringer Mannheim. Recombinant human IGF-I and rat IGF-II were
purchased from Bachem, Inc. (Torrance, CA). Human IGFBP-4 and
IGFBP-5 were purified as described previously (19).
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Cell Culture—Porcine aortic smooth muscle cells (VSMCs) were iso-
lated from thoracic aorta of 3-week-old piglets. The cells were grown in
10-cm dishes (Falcon, Becton Dickinson Labware, Franklin Lakes, NJ)
in DMEM supplemented with glutamine (4 mM), penicillin (100 units/
ml), and streptomycin (100 mg/ml) plus 10% fetal bovine serum. The
medium was changed every fourth day until the cells became confluent.
Western Ligand Blot and Immunoblot Analysis—In order to identify
the forms of IGFBPs secreted by VSMCs, samples were concentrated 20
times by ultrafiltration through a Centricon-10 microconcentrator
(Amicon, Berkeley, MA). The volume of conditioned medium that was
analyzed was adjusted for difference in cell number. The proteins were
separated by SDS-polyacrylamide gel electrophoresis using 12.5% poly-
acrylamide gels under nonreducing conditions. After transfer to filters
(Immobilon P, 0.45-mm pore size, Millipore Corp., Bedford, MA), the
filters were probed with 125I-IGF-I, and autoradiographs were obtained
as described previously (14).
Immunoprecipitation—Cells were grown in 10-cm dishes (Falcon)
and rinsed three times with serum-free DMEM before being incubated
in serum-free DMEM containing 100 mg/ml heparin for 8 h. Media were
collected, and IGFBP-5 was immunoprecipitated from the media by the
addition of an anti-human IGFBP-5 antibody (prepared in guinea pig,
1:1000 dilution) or normal guinea pig serum (control). IGFBP-2 was
immunoprecipitated from the same media by the addition of an anti-
bovine IGFBP-2 antiserum. The volume of conditioned medium used
was normalized by cell number. The immune complexes were precipi-
tated by adding protein A-Sepharose (Sigma) and analyzed by 12.5%
SDS-polyacrylamide gel electrophoresis gels followed by Western ligand
blotting.
To quantify the IGFBP-5 concentrations, known amounts of pure
human IGFBP-5 (2–200 ng) were added to parallel lanes, and the band
intensities of the unknown samples were compared with those obtained
using the pure human IGFBP-5 standard. The lower limit of detection
was 25 ng/ml. To quantify IGFBP-4, the media samples were concen-
trated (20-fold) and then analyzed by SDS-polyacrylamide gel electro-
phoresis with immunoblotting as described previously (13). The band
intensities were quantified by PhosphorImager image analysis using
ImageQuant (Molecular Dynamics, Inc.). Image intensities were com-
pared with the known pure human IGFBP-4 standards that were ana-
lyzed on the same gel to calculate the IGFBP-4 concentrations. The
lower limit of detection was 50 ng/ml. To determine IGF-I concentra-
tions, the conditioned media were extracted using a Sep-Pak C-18
cartridge (20) (Millipore) to remove all of the IGFBPs. The extracts were
then analyzed by a specific IGF-I radioimmunoassay.
RNA Isolation and Northern Blot Analysis—RNA was isolated from
cell cultures using TriReagent following the manufacturer’s instruc-
tions (Molecular Research Center, Inc., Cincinnati, OH) and was quan-
tified by measuring UV absorption at an OD of 260 nm. RNA samples
were size-fractionated on a 1.2% agarose-formaldehyde gel, blotted, and
fixed onto a nylon membrane (ICN Biochemical, Inc., Irvine, CA). They
were hybridized with the [32P]dCTP-labeled human IGFBP cDNAs (14).
A cDNA probe for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Ambion, Austin, TX) was used to determine that the same
amount of RNA was loaded. The band densities were quantified by
exposing the filters to phosphor screens, which were scanned on Phos-
phorImager SF followed by image analysis using ImageQuant software
(Molecular Dynamics).
Protease Assays—To study the change in IGFBP-4 and IGFBP-5
protease activity, VSMC-conditioned media were collected and stored at
220 °C until used. The conditioned media were incubated with 50 ng of
pure human IGFBP-4 or IGFBP-5 for 14 h at 37 °C in 60 ml of Tris (50
mM) containing 50 mM NaCl and 2.0 mM CaCl2 (pH 7.4). For IGFBP-4
protease assays, 50 ng/ml IGF-I was included in the incubation mix-
ture. The digestion products were analyzed by immunoblotting as de-
scribed above.
[3H]Thymidine Incorporation Assay—To determine the rate of DNA
synthesis, porcine VSMCs were plated onto 96-well plates (Falcon) at
10,000 cells/well in DMEM supplemented with 10% fetal bovine serum
and incubated for 3 days without a medium change. After being rinsed
three times with DMEM, the cultures were exposed to DMEM that
contained 1 mCi of [3H]thymidine (ICN Biochemicals, Inc., CA), 0.2%
human platelet poor plasma, and the stated concentration of IGF-I
and/or IGFBP in a final volume of 200 ml. Each treatment was added to
triplicate cultures. After 24–48 h, media were collected for ligand and
immunoblotting analysis. Cells were then washed twice with phos-
phate-buffered saline and twice with cold 5% trichloroacetic acid for 10
min at 4 °C and solublized in 200 ml of 0.1 M NaOH and 1% SDS at room
temperature for 1 h. The solublized DNA was harvested for liquid
scintillation counting. The results are expressed as the percentage
change from the IGF-I alone controls.
Statistical Analysis—Student’s t test was used to compare the differ-
ence between the control and test groups. Values are means 6 S.E. p ,
0.05 is considered significant.
RESULTS
IGFBPs Secreted by Porcine VSMCs—The ligand blotting
analysis of conditioned, serum-free medium of subconfluent
porcine VSMCs revealed two major bands of approximately 24
and 30–32 kDa (Fig. 1A). The 24-kDa protein has previously
been identified as IGFBP-4 (13). The 30–32-kDa doublet band
is a mixture of IGFBP-2 and IGFBP-5. Since these two proteins
are similar in size (e.g. 32 and 31 kDa) and indistinguishable by
ligand blot analysis, they were further separated by immuno-
precipitation and analyzed by ligand blot analysis (Fig. 1, B
and C). Northern blotting analysis revealed the expression of
IGFBP-2, IGFBP-4, and IGFBP-5 mRNA (data not shown), a
finding that is consistent with the protein results. These re-
sults indicate that porcine VSMCs synthesize and secrete three
IGFBPs, namely IGFBP-2, IGFBP-4, and IGFBP-5.
Culture Density-dependent Expression of IGFBPs—Condi-
tioned media were collected from porcine VSMCs growing at
three different densities and subjected to immunoprecipitation
and ligand blot analysis. As shown in Fig. 2, the accumulated
levels of IGFBP-4 and IGFBP-5 varied substantially, depend-
ing on culture density. While the IGFBP-2 levels remained the
same under these conditions, the IGFBP-4 levels increased
significantly with increasing culture density (Fig. 2). When
IGFBP-4 in the medium was quantified by comparing its band
intensity to known standards, the concentration increased from
,50 ng/ml to 742 6 105 ng/ml (mean 6 S.D. of three separate
experiments). In contrast, the IGFBP-5 levels decreased dra-
matically with the increase in culture density. When IGFBP-5
was quantified, it decreased from 792 6 91 to 44 6 14 ng/ml in
media from the high density cultures. IGF-I also decreased
from 94 6 14 ng/ml in the sparse cultures to 18 6 9 ng/ml in the
high density cultures.
To determine if these changes in IGFBP levels were regu-
lated at the level of mRNA abundance, total RNA was isolated
and then subjected to Northern blot analysis. No significant
change in IGFBP-2 mRNA was observed (Fig. 3). The IGFBP-4
mRNA levels showed a small decrease (,30%). This result was
not in agreement with the substantial increase in the accumu-
lated IGFBP-4 levels in the conditioned medium (Fig. 2). On
the other hand, the cell density-dependent increase in accumu-
lated IGFBP-5 was accompanied by a comparable increase in
IGFBP-5 mRNA levels. The steady-state levels of IGFBP-5
mRNA levels decreased rapidly with the increasing culture
density (Fig. 3). The IGFBP-5 mRNA levels in confluent cul-
tures were 2.6-fold higher in sparse cultures as compared with
those of confluent cultures, suggesting that this change in
FIG. 1. IGFBPs secreted by cultured porcine VSMCs. A, ligand
blot analysis of the medium conditioned by porcine VSMCs. B, immu-
noprecipitation and ligand blotting analysis of IGFBP-2. The same
conditioned medium samples shown in A were immunoprecipitated
with an anti-bovine IGFBP-2 antibody prior to ligand blot analysis. C,
immunoprecipitation and ligand blotting analysis of IGFBP-5. The
same conditioned medium samples shown in A were immunoprecipi-
tated with an anti-human IGFBP-5 antibody prior to ligand blot
analysis.
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IGFBP-5 is attributable at least in part to altered synthesis.
Since porcine VSMCs are known to secrete proteases for
IGFBP-4 and IGFBP-5, the conditioned media were analyzed to
determine if changes in culture density were associated with
potential changes in IGFBP-4 and IGFBP-5 protease activity.
Analysis of the IGFBP-4 protease activity in vitro showed that
it was greatly decreased when cells reached confluence, as
evidenced by the decreased proteolytic fragment formation
(Fig. 4A). In comparison, only a small increase in the IGFBP-5
protease activity was detected (Fig. 4B), and this change was
not sufficient to explain the dramatic decrease in intact IG-
FBP-5 in the media from confluent cultures.
IGF-I is an Autocrine/paracrine Regulator of IGFBPs in
VSMCs—As shown in Fig. 3, the steady-state levels of IGFBP-5
mRNA were significantly lower in confluent cultures. The cul-
ture density-dependent decrease in IGFBP-5 mRNA levels cor-
related well with a culture density-dependent decrease in the
endogenous IGF-I levels that had been previously shown in this
culture system (5). To examine the potential role of IGF-I as an
autocrine/paracrine regulator of IGFBP-5 synthesis, IGF-I was
added exogenously to confluent and sparse cultures. In the
confluent cultures where the endogenous IGF-I is low, the
IGFBP-5 mRNA levels were lower (40% of those in sparsely
growing cultures). Adding exogenous IGF-I increased the
steady-state levels of IGFBP-5 mRNA to levels comparable
with those in the sparsely growing cultures (Fig. 5). We next
neutralized the endogenously secreted IGF-I in sparsely grow-
ing cultures using an IGF-I-neutralizing antibody (Sm 1.2) and
examined its effect on IGFBP-5 gene expression. As shown in
Fig. 6, the IGFBP-5 mRNA levels were significantly higher in
the sparsely grown cells compared with confluent control (lanes
1 and 2). When the monoclonal IGF-I antibody, Sm 1.2, was
added to the cultures at the dilution rates of 1:2000 and 1:500,
the IGFBP-5 mRNA levels were significantly decreased (lanes
3 and 4). Normal mouse IgG at the same concentration had no
effect. These results indicate that the IGFBP-5 synthesis is
regulated by the endogenously produced IGF-I.
Distinct Biological Effects of IGFBP-4 and IGFBP-5 in
VSMCs—To determine the role that each IGFBP plays in reg-
ulating the action of IGF-I on VSMC proliferation, increasing
concentrations of IGFBP-4 and IGFBP-5 were added to quies-
cent cultures in the presence of 50 ng/ml of IGF-I. IGF-I alone
caused a 200 6 32% increase in [3H]thymidine incorporation
(mean of seven experiments). Co-incubation of IGFBP-4 for
48 h inhibited the effect of IGF-I in a dose-dependent manner
(Fig. 7A). This inhibition was significant at the higher concen-
trations (p , 0.05). At lower concentrations, nearly all of the
IGFBP-4 was degraded (Fig. 7B), and the inhibition was
FIG. 3. Effects of cell density/confluence on the steady-state
levels of IGFBP mRNA in porcine VSMC cultures. Confluent
(Conf), subconfluent (Subconf), and sparse porcine VSMC cultures were
exposed to serum-free medium for 24 h. Total RNA were isolated and
subjected to Northern blot analysis using cDNA probes for IGFBP-2,
IGFBP-4, IGFBP-5, and GAPDH. PhosphorImager analysis of three
experiments was shown. Values are means 6 S.E. (n 5 3) expressed as
a percentage of mRNA levels in the confluent cultures.
FIG. 4. Effects of cell density/confluence on IGFBP-4 (A) and
IGFBP-5 (B) protease activity in porcine VSMC cultures. Exoge-
nous human IGFBP-4 or IGFBP-5 (50 ng) was incubated with media
conditioned by subconfluent (Subconf) and confluent (Conf) porcine
VSMCs in the presence of IGF-I for 14 h. Samples without conditioned
medium were incubated for 14 h as controls. Intact IGFBP as well as
proteolytic fragments were detected by immunoblot analysis.
FIG. 2. Effects of cell density/confluence on IGFBP levels in
porcine VSMC cultures. Serum-free medium was conditioned by
confluent (Conf), subconfluent (Subconf), and sparse porcine VSMCs for
24 h and subjected to ligand blot analysis (IGFBP-4) or immunoprecipi-
tation followed by ligand blot analysis (IGFBP-2 and IGFBP-5) as
described under “Experimental Procedures.” The band intensities were
quantified by PhosphorImager analysis. Values are means 6 S.E. (n 5
3) expressed as a percentage of the confluent cultures.
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moderate.
In contrast to IGFBP-4, IGFBP-5 increased the IGF-I-stim-
ulated thymidine incorporation when incubated together with
IGF-I for 48 h (Fig. 8A). This potentiating effect was statisti-
cally significant at 0.5 mg/ml (p , 0.05). The potentiating effect
of IGFBP-5 on the IGF-I-stimulated DNA synthesis appeared
to require a long incubation period. When incubated with IGF-I
for 24 h, IGFBP-5 had no potentiating effect (data not shown).
We further examined the degradation of the exogenous IG-
FBP-5 under these assay conditions. As shown in Fig. 8B, with
the exception of the highest concentration (1 mg/ml), the exog-
enously added IGFBP-5 was completely degraded after a 48-h
incubation. The disappearance of intact IGFBP-5 appeared to
be associated with the potentiation effect of IGFBP-5 in porcine
VSMCs.
DISCUSSION
Porcine VSMCs have been previously shown to synthesize
and secrete three forms of IGFBPs including IGFBP-2, IG-
FBP-4, and IGFBP-5 (13, 14). The results of this study indicate
that IGFBP-4 and IGFBP-5 are differentially regulated by the
autocrine/paracrine secretion of IGF-I. IGF-I decreases IG-
FBP-4 concentrations by activating its proteolytic cleavage,
whereas it increases IGFBP-5 by stimulating gene expression.
IGFBP-4 and IGFBP-5, in turn, play opposing roles in modu-
lating IGF-I action. IGFBP-4 inhibits IGF-I-stimulated DNA
synthesis, whereas IGFBP-5 has potentiating effects. These
results indicate an IGF-I-regulated autocrine loop is present
and plays an important role in regulating cell proliferation in
porcine VSMCs.
In rat aortic VSMCs, the basal IGFBP-3 levels were higher,
while IGFBP-2 levels were lower in confluent cultures as com-
pared with subconfluent cultures (17). The biosynthesis and
proteolytic cleavage of IGFBP-4 were higher in confluent as
compared with sparse cultures. As a result, the accumulated
FIG. 6. Neutralizing endogenous IGF-I decreases IGFBP-5
gene expression in sparsely growing porcine VSMCs. A, autora-
diogram showing the effect of neutralizing endogenous IGF-I. Confluent
(lane 1) and sparse VSMC cultures (lanes 2–5) were exposed to serum-
free medium for 24 h without (lanes 1 and 2) or with the 1:2000 (lane 3)
or 1:500 (lane 4) dilutions of the monoclonal IGF-I antibody Sm 1.2 or
mouse IgG (lane 5). Total RNA was isolated from VSMC cultures and
subjected to Northern blotting with cDNA probes for IGFBP-5 and
GAPDH. B, PhosphorImager analyses. Values are the means of two
experiments. They are expressed as a percentage of mRNA levels in the
confluent, untreated control cultures.
FIG. 5. IGF-I treatment increases IGFBP-5 gene expression in
confluent porcine VSMC cultures. A, autoradiogram showing the
effects of exogenously added IGF-I to confluent (lanes 1 and 2) cultures
and sparsely growing cultures (lanes 3 and 4). Porcine VSMCs were
incubated in serum-free medium without (lanes 1 and 3) or with IGF-I
(100 ng/ml, lanes 2 and 4) for 24 h. Total RNA was isolated and
subjected to Northern blotting with cDNA probes for IGFBP-5 and
GAPDH. B, PhosphorImager analyses. Values are the means of two
experiments. They are expressed as percentages of mRNA levels in the
confluent, untreated control cultures.
FIG. 7. A, effect of human IGFBP-4 on IGF-I-stimulated DNA syn-
thesis in porcine VSMCs. Cells were plated as described under “Exper-
imental Procedures” and incubated 3–5 days without a medium change.
Cultures were then exposed to serum-free medium containing [3H]thy-
midine, 0.2% human platelet-poor plasma, IGF-I (50 ng/ml), and the
concentrations of IGFBP that are shown. After 48 h, [3H]thymidine
incorporation into DNA was determined as described under “Experi-
mental Procedures.” The results are expressed as the percentage in-
crease over control cultures exposed to IGF-I and platelet-poor plasma
alone. Values are the means 6 S.E. of four experiments. Each experi-
ment point was performed in triplicate for each experiment. *, p , 0.05.
B, immunoblot analysis of the added IGFBP-4 in the medium at the
termination of the thymidine incorporation experiments. Intact human
IGFBP-4 as well as proteolytic fragments were detected by an anti-
human IGFBP-4 antiserum and are indicated by arrows.
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IGFBP-4 levels remained unchanged (17). In the porcine VSMC
cultures, the accumulated IGFBP-4 protein levels increased
significantly when cultures reached confluence. This increase
in IGFBP-4 protein levels is not associated with any increase in
IGFBP-4 mRNA levels, suggesting that it is not due to alter-
ation in IGFBP-4 biosynthesis. Porcine VSMCs have been
shown to secrete a protease(s) that degrades IGFBP-4 (13, 21).
This enzyme(s) is a calcium-dependent serine protease with an
estimated molecular size of 48 kDa (21). Although minimal
proteolytic activity can be detected in the absence of IGF-I or
IGF-II, when either of these growth factors is present the rate
of proteolysis is greatly accelerated (13, 21). A major decrease
in the IGFBP-4 protease activity was detected when cells
reached confluence, suggesting that the increased IGFBP-4
level associated with confluence is probably due to the de-
creased IGF-I-dependent proteolysis.
A novel observation made in this study is the culture density-
dependent expression of IGFBP-5. In contrast to IGFBP-4, the
accumulated IGFBP-5 levels were higher in sparse, proliferat-
ing cultures. When cells reached confluence, the IGFBP-5 lev-
els declined to nearly undetectable levels. Because porcine
VSMCs secrete abundant protease activity that degrades IG-
FBP-5 (14), we examined whether the change in IGFBP-5
might be regulated by variations in the IGFBP-5 protease. This
appears unlikely, since there was no substantial change in
IGFBP-5 protease activity when low and high density cultures
were compared. Instead, an increase in IGFBP-5 mRNA levels
was detected by Northern blot analysis, suggesting that the
change in IGFBP-5 is probably due to an increase in the syn-
thesis of this protein.
The inverse correlation between IGFBP-5 abundance and
culture density mimics that of the endogenous IGF-I reported
previously (5). Previously we have shown that the addition of
IGF-I to VSMC cultures significantly increases the IGFBP-5
concentrations. This increase in IGFBP-5 is primarily due to an
increase in its synthesis (14). In light of the close correlation
between endogenous IGF-I and IGFBP-5 concentrations and
the fact that exogenously added IGF-I stimulates IGFBP-5
synthesis, we investigated whether the change in IGFBP-5
might be regulated by variations in the endogenous IGF-I.
Neutralization of the endogenous IGF-I with an anti-IGF-I
antibody clearly suppressed the IGFBP-5 mRNA expression to
the levels of the confluent cultures. Therefore, the endogenous
IGF-I, whose expression is also inversely correlated with the
culture density (5), may play an important role in determining
the relative abundance of IGFBP-4 and IGFBP-5.
The underlying molecular mechanism(s) that regulates cul-
ture density/confluence-dependent expression of the IGF-I gene
is unclear. There are several examples of cell density-depend-
ent expression of other proteins/genes in VSMCs. The levels of
type III collagen and fibronectin mRNA have been shown to be
increased in confluent, quiescent VSMCs (22). In mouse
BC3H1 cells, a cell line derived from cerebrovascular VSMCs,
the smooth muscle cell a-actin gene is maximally induced in
confluent cultures (23). A “cell density-responsive element” has
been identified in the promoter region of this gene (24). Further
effort is needed to determine if a similar cell density-responsive
element is present and functional in the IGF-1 gene promoter.
The results of this study demonstrate that IGFBP-4 inhibits,
while IGFBP-5 potentiates, IGF-I-stimulated VSMC prolifera-
tion under identical culture conditions and that both effects
could be demonstrated using concentrations of IGFBP-4 and -5
that were within the range of those endogenously produced by
sparse (IGFBP-5) or confluent (IGFBP-4) VSMC cultures. The
inhibitory effect of IGFBP-4 on IGF-stimulated cell prolifera-
tion is not unique to VSMCs. IGFBP-4 has been consistently
shown to be an inhibitory IGFBP in many other cell types (25).
A previous study, however, failed to show such an effect in
cultured porcine VSMCs. Identical concentrations of IGFBP-4,
however, inhibited the effect of IGF-I on fibroblast growth. This
is probably due to the presence of IGFBP-4 protease activity in
VSMC cultures. When a limited amount of IGFBP-4 is added,
it is degraded rapidly, and this probably explains why low
concentrations of IGFBP-4 did not inhibit IGF-I action (13).
When higher concentrations of IGFBP-4 were tested (e.g. .0.5
mg/ml), some intact protein could be detected, and an inhibitory
effect was noted.
In contrast to the inhibitory effect of IGFBP-4, IGFBP-5 has
been shown to be capable of both inhibiting and potentiating
the IGF-I actions in other cell types (26–29). In porcine
VSMCs, IGFBP-5 potentiated the IGF-I-induced increase of
DNA synthesis. Relatively high concentrations (0.5 mg/ml) and
long incubation times (48 h) were required for its potentiation
effect. When incubated for a relatively short time (24 h), we
found that high concentrations of IGFBP-5 had a moderate
inhibitory effect (data not shown). We examined the degrada-
tion of the exogenously added IGFBP-5 under these conditions.
Almost all of the added IGFBP-5 was degraded after more than
48 h of incubation, but a substantial proportion of IGFBP-5
remained intact within the first 24 h of incubation. Therefore,
the difference in the degree of IGFBP-5 proteolysis may explain
the different results. Intact IGFBP-5 in the culture medium
FIG. 8. A, effect of human IGFBP-5 on IGF-I-stimulated DNA syn-
thesis in porcine VSMCs. Cells were plated as described under “Exper-
imental Procedures” and incubated 3–5 days without a medium change.
Cultures were then exposed to serum-free medium containing [3H]thy-
midine, 0.2% platelet-poor plasma, IGF-I (50 ng/ml), and the concen-
trations of IGFBP-5 that are shown. After 48 h, [3H]thymidine incor-
poration into DNA was determined as described under “Experimental
Procedures.” The results are expressed as the percentage increase over
control cultures exposed to IGF-I and human platelet-poor plasma
alone. Values are the means 6 S.E. of three experiments. Each exper-
iment point was performed in triplicate for each experiment. *, p , 0.05.
B, immunoblot analysis of the added IGFBP-5 in the medium at the
termination of the thymidine incorporation experiments. Intact human
IGFBP-5 as well as proteolytic fragments were detected by an anti
human IGFBP-5 antiserum and are indicated by arrows.
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binds to IGF-I with a high affinity that is at least 10-fold
greater than the IGF-I receptor (25). Consequently, when it is
added to the culture medium it limits receptor association (30).
Under conditions in which long incubation times are used,
most, if not all, of the added IGFBP-5 is degraded into a 21-kDa
fragment. This fragment has very low affinity for IGF-I (14).
This switch in binding affinity results in the equilibrium favor-
ing binding of IGF-I to its receptor. This hypothesis is sup-
ported by the recent observation that high concentrations of a
mutant form of IGFBP-5 that is protease-resistant inhibits
IGF-I actions in porcine VSMCs (30). Alternatively, this poten-
tiating effect of IGFBP-5 may be related to its capacity to bind
to extracellular matrix (ECM) proteins (31). Jones et al. (26)
have shown that ECM-bound IGFBP-5 potentiates, while sol-
uble IGFBP-5 added to the cultures inhibits, IGF-I-induced cell
proliferation in human fibroblasts. The ECM-bound IGFBP-5
has an affinity for IGF-I that is 8-fold lower than the IGF-I
receptor, thus permitting better equilibration. The ECM-asso-
ciated IGFBP-5 is also resistant to proteolysis (31). Therefore,
the major function of the protease may be to limit the amount
of intact IGFBP-5 in the conditioned medium while allowing
the ECM-associated IGFBP-5 to accumulate.
We propose, based on the findings of this and previous stud-
ies, a model to explain the potential mechanism by which
members of the IGF family interact with each other to deter-
mine the cellular response in VSMCs (Fig. 9). The endogenous
IGF-I, whose expression is inversely correlated with culture
density, plays an central role in controlling IGFBP-4 and IG-
FBP-5 concentrations. In the sparse/proliferating cells, the
IGF-I expression is high, and it increases IGFBP-5 concentra-
tions by stimulating gene expression. It decreases IGFBP-4
concentrations through activating proteolysis. The relatively
higher IGFBP-5 and lower IGFBP-4 levels in turn result in a
greater mitogenic response to IGF-I. In the confluent/differen-
tiated cells, the expression of IGF-I and therefore IGFBP-5 is
low, and the intact IGFBP-4 level is increased due to the
decreased IGF-dependent proteolysis. As a result, there is an
attenuation of cellular response to IGF-I.
Other investigators have reported a relationship between
the confluence or differentiation state of various cell types and
the relative abundance of IGFBPs. In human colon cancer
CaCo2 cells, which express and secrete IGF-II and IGFBP-2
and IGFBP-4, proliferating cells express abundant IGF-II and
low quantities of inhibitory IGFBP-4, while differentiated cells
secrete abundant IGFBP-4 and virtually undetectable IGF-II
(32). In MC3T3-E1 murine osteoblasts, IGFBP-2 and IGFBP-4
are produced at their highest concentrations in differentiated
cells, while IGFBP-5 production is higher in proliferating cells
(33). Similar elevated expression associated with confluency
was also noted for another inhibitor of IGFs, IGFBP-6, in
keratinocytes and myoblasts (34, 35). During the differentia-
tion of mouse C2 myoblasts in culture, proliferating cells ex-
press negligible amounts of IGFBP-5 (36, 37). In response to
switching to a differentiation medium, myoblasts exit the cell
cycle and commence along a differentiation pathway that is
accompanied by an extensive induction of IGFBP-5. In this
system, however, the levels of endogenous IGFs also increased
during the differentiation. It would appear, therefore, the ex-
pression of IGFs and IGFBPs is coordinately regulated in re-
sponse to changes in culture confluence/cell differentiation
state in many cell types. Analysis of the mechanisms that
control culture density/confluence-dependent changes in IGF-I
and IGFBP expression may have important implications for
understanding the molecular mechanisms underlying cell
growth and differentiation in VSMCs.
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